NeoVentures has successfully developed aptamers for both the spike protein and the nucleoprotein of SARS-CoV-2 (COVID-19). Spike protein aptamers were developed against a recombinant S1 protein from the Wuhan strain expressed in HEK293 cells in order to maintain appropriate glycosylation, counter selection was performed against… Read More »Neo Ventures Announcement
Why are there not more aptamer based therapeutics? This blog by Drew Smith in 2019 nails a lot of the reasons, and in particular the issues related to the rapid clearance of aptamers from the body. https://drewsmithblog.com/2019/05/aptamers-still-looking-for-euphoria-in-the-wrong-places/. He effectively points out that the aptamer that… Read More »Aptamers in therapeutics ? (Why not)
In a previous blog I stressed the need to further improve aptamer performance after SELEX identification in order to develop aptamers that are effective enough to be commercialized. I promised that I would describe how we do this at NeoVentures in more detail in a… Read More »Optimized Aptamers II
The difficulty of working with antibodies and the ease of working with aptamers. Can you imagine selling a product for which you do not really know how much you are selling. Imagine having to describe the amount of product to clients by saying that you… Read More »PRODUCT DEVELOPMENT CLARITY WITH APTAMER
For aptamers to be able to compete with antibodies in health care applications they need to perform as well as antibodies. At NeoVentures we have considered how antibodies evolve in response to an antigen and we have applied a similar approach to the optimization of… Read More »Optimized Aptamers
Aptamers are oligonucleotides (single stranded DNA or RNA) that mimic antibodies in their ability to bind to target molecules. Aptamers are not derived from living organisms, they have nothing to do with life. We start with a library of random sequences and identify those that… Read More »Why should you be interested in Aptamers?